Literature DB >> 15351923

Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro.

Einosuke Tanaka1, Yui Takano, Shinichi Inomata, Hidenori Toyooka, Katsuya Honda.   

Abstract

OBJECTIVE: Propofol (2,6-diisopropylphenol) is widely used for anesthetic induction as well as for chronic sedation in intensive care units. In this study, we investigated the interaction between propofol and premedications, i.e., psychotropic and antianxiety agents (diazepam, midazolam), hypnotics (thiamylal), local anesthetics (lidocaine), depolarizing muscular relaxants (vecuronium), an antihypertensive (clonidine) and an H2-receptor antagonist (cimetidine) using human liver microsomes in vitro.
METHODS: The interaction effects between propofol and premedications were examined using human liver microsomal preparation in vitro. The concentration of propofol was determined by HPLC with UV detection.
RESULTS: The apparent Michaelis-Menten constant (Km) and the maximal velocity of total metabolic formation (Vmax) of propofol in human liver microsomes were 123 microM and 26.1 micromol/min per milligram of mg protein, respectively. Seven premedications (diazepam, midazolam, thiamylal, lidocaine, cimetidine, vecuronium, and clonidine) did not inhibit propofol metabolism in human liver microsomes at concentrations within the therapeutic range.
CONCLUSIONS: These results showed no interactions between propofol and seven premedication drugs within the therapeutic range of propofol using human liver microsomes in vitro.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15351923     DOI: 10.1007/s00228-004-0807-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

Review 1.  Propofol: a new intravenous anesthetic.

Authors:  P S Sebel; J D Lowdon
Journal:  Anesthesiology       Date:  1989-08       Impact factor: 7.892

2.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Authors:  T Kronbach; D Mathys; M Umeno; F J Gonzalez; U A Meyer
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

3.  The effect of propofol on midazolam metabolism in human liver microsome suspension.

Authors:  B P Leung; E Miller; G R Park
Journal:  Anaesthesia       Date:  1997-10       Impact factor: 6.955

4.  Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.

Authors:  M H Court; S X Duan; L M Hesse; K Venkatakrishnan; D J Greenblatt
Journal:  Anesthesiology       Date:  2001-01       Impact factor: 7.892

5.  Monospecific antipeptide antibody to cytochrome P-450 2B6.

Authors:  D M Stresser; D Kupfer
Journal:  Drug Metab Dispos       Date:  1999-04       Impact factor: 3.922

6.  Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.

Authors:  N Hamaoka; Y Oda; I Hase; K Mizutani; T Nakamoto; T Ishizaki; A Asada
Journal:  Clin Pharmacol Ther       Date:  1999-08       Impact factor: 6.875

7.  Inhibitory effects of propofol on cytochrome P450 activities in rat hepatic microsomes.

Authors:  M T Baker; M V Chadam; W C Ronnenberg
Journal:  Anesth Analg       Date:  1993-04       Impact factor: 5.108

Review 8.  Drug-mediated inactivation of cytochrome P450.

Authors:  M Murray
Journal:  Clin Exp Pharmacol Physiol       Date:  1997-07       Impact factor: 2.557

Review 9.  Interactions between antipsychotic and antihypertensive drugs.

Authors:  J S Markowitz; B G Wells; W H Carson
Journal:  Ann Pharmacother       Date:  1995-06       Impact factor: 3.154

10.  Human cytochrome P450 mono-oxygenase system is suppressed by propofol.

Authors:  T L Chen; T H Ueng; S H Chen; P H Lee; S Z Fan; C C Liu
Journal:  Br J Anaesth       Date:  1995-05       Impact factor: 9.166

View more
  2 in total

1.  Effect of propofol on ropivacaine metabolism in human liver microsomes.

Authors:  Yoshiko Osaka; Shinichi Inomata; Einosuke Tanaka; Takako Nakamura; Katsuya Honda; Masayuki Miyabe; Hidenori Toyooka; Makoto Tanaka
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

Review 2.  Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4.

Authors:  Stéphane Mouly; Christophe Meune; Jean-François Bergmann
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.